Please assess the completion status of the following clinical trial:

Trial Title: N-Acetyl-Cysteine (NAC) for Healing of Amputation Stumps in the Setting of Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject undergoing elective major (above-knee or below-knee) lower extremity amputation for CLI~* Both male and female patients~* All ethnic groups~* Between of the ages of 30-90 years old~* Adequate nutritional status - defined as BMI \> 19~Exclusion Criteria:~* Pregnant women, and women who are breastfeeding~* Known history of end-stage liver disease~* Severe asthma~* Heavy alcohol consumption (male \> 2 drinks per day and women \> 1 drink per day)~* Individuals actively receiving chemotherapy.~* Anticipated enrollment in another study that investigates another drug agent within 30 days from enrollment in this study.~* Patients receiving carbamazepine.~* Severe anemia (HCT \< 22).~* Allergy to either NAC or Indocyanine Green (ICG).~* Patients with open wound(s) from a prior amputation on the ipsilateral limb (excluding patients who had prior partial foot amputation, who are now requiring a below-knee or above-knee amputation).

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Active Arm N-acetyl cysteine (NAC) (Type: ACTIVE_COMPARATOR): Upon study enrollment, patients will be randomized 1:1 by Investigational Pharmacy to a standard adult intravenous dose of NAC (1200mg twice a day) for 6 days post-amputation.
- Placebo Arm (Type: PLACEBO_COMPARATOR): Upon study enrollment, patients will be randomized 1:1 by Investigational Pharmacy to placebo ½ normal saline infusion (twice a day) for 6 days post-amputation.

Based on this trial design, predict the completion outcome and termination type (if applicable).